title: Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study.
abstract: We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary thromboembolism who had not received any other anticoagulant and had received no more than 36 hours of treatment with unfractionated heparin were included. Post RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that were analyzed based on major or minor bleeding events. In addition, blood flow velocity was determined. No complete occlusive thrombus or bleeding events were reported with either of the group. The lower incidence rate of non-occluded thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates rivaroxaban may be administered post-RFCA to prevent and treat femoral venous thrombosis in a secure and effective way with a faster inset of action than standard aspirin therapy.
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Lan
authors.initials: L
authors.lastname: Li
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Bao-Jian
authors.initials: BJ
authors.lastname: Zhang
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Bao-Ku
authors.initials: BK
authors.lastname: Zhang
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Xu-Zheng
authors.initials: XZ
authors.lastname: Liu
authors.affiliation: Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
authors.forename: Shu-Bin
authors.initials: SB
authors.lastname: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001145:Arrhythmias, Cardiac / Q000601:surgery*; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D017115:Catheter Ablation / Q000009:adverse effects*; D002681:China; D005260:Female; D005268:Femoral Vein; D006801:Humans; D035002:Lower Extremity; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000069552:Rivaroxaban; D001241:Aspirin